It is because hemp only recently became legal to grow in the U.S. that many of the finished hemp goods that you see for sale in America, from food products to clothing to building materials, are part of an imported hemp industry that has surpassed $688 million annually. The size of this import industry was one of the major catalysts for hemp legalization in the U.S. As a renewable source of a range of products, hemp provides an exciting new step in American agriculture.

Multiple sclerosis (MS). There is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness in people with MS. However, it does not appear to improve muscle spasms, tiredness, bladder control, the ability to move around, or well-being and quality of life.


Some preliminary research suggests that CBD may help with arthritis pain. In animal studies, which may not translate to humans, CBD relieved arthritis pain and inflammation. On the other hand, results of human studies are mixed. For example, a 2016 analysis of human trials for RA, OA and fibromyalgia found that CBD improved pain and sleep, but the studies were small and of poor quality.
We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our Advertising Policy and Privacy Policy. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.
Developed for the pharmacy sector, Canabidol™ products meet the exacting standards required by pharmacists for the retail sale of CBD. One of the longest standing brands in the UK, Canabidol™ has spearheaded the industry with it our dedication to excellence, passion for compliance and commitment to getting things right. The result has seen Canabidol™ products become the market leading brand in the pharmacy sector, with thousands of customers preferring Canabidol™. Which is now the only brand of choice in the UK, it’s the reason our thousands of registered official resellers now stock our products in high streets and major retail outlets across the country.
Seizure disorder (epilepsy). A specific cannabidiol product (Epidiolex, GW Pharmaceuticals) has been shown to reduce seizures in adults and children with various conditions that are linked with seizures. This product is a prescription drug for treating seizures caused by Dravet syndrome or Lennox-Gastaut syndrome. It has also been shown to reduce seizures in people with tuberous sclerosis complex, Sturge-Weber syndrome, febrile infection-related epilepsy syndrome (FIRES), and specific genetic disorders that cause epileptic encephalopathy. But it's not approved for treating these other types of seizures.
Prescription medicine (Schedule 4) for therapeutic use containing 2 per cent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆9-THC). A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.[57] cannabidiol oil
×